MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.medj.2024.07.002

Медицинская библиотека · Med (New York, N.Y.) · 2024

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer.

Yang Zhengyang, Ma Jingxin, Han Jiagang, Li Ang, Liu Gang, Sun Yi, Zheng Jianyong, Zhang Jie, Chen Guangyong, Xu Rui, Sun Liting, Meng Cong, Gao Jiale, Bai Zhigang, Deng Wei, Zhang Chenlin, Su Jianrong, Yao Hongwei, Zhang Zhongtao

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Accurate evaluation of the response to preoperative treatment enables the provision of a more appropriate personalized therapeutic schedule for locally advanced rectal cancer (LARC), which remains an enormous challenge, especially neoadjuvant immunotherapy plus chemoradiotherapy (nICRT).

METHODS

This prospective, multicenter cohort study enrolled patients with LARC from 6 centers who received nICRT. The dynamic variation in the gut microbiome during nICRT was evaluated. A species-level gut microbiome prediction (SPEED) model was developed and validated to predict the pathological complete response (pCR) to nICRT.

FINDINGS: A total of 50 patients were enrolled, 75 fecal samples were collected from 33 patients at different time points, and the pCR rate reached 42.4% (14/33). Lactobacillus and Eubacterium were observed to increase after nICRT. Additionally, significant differences in the gut microbiome were observed between responders and non-responders at baseline. Significantly higher abundances of Lachnospiraceae bacterium and Blautia wexlerae were found in responders, while Bacteroides, Prevotella, and Porphyromonas were found in non-responders. The SPEED model showcased a superior predictive performance with areas under the curve of 98.80% (95% confidence interval [CI]: 95.67%-100%) in the training cohort and 77.78% (95% CI: 65.42%-88.29%) in the validation cohort.

CONCLUSIONS

Programmed death 1 (PD-1) blockade plus concurrent long-course CRT showed a favorable pCR rate and is well tolerated in microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) patients with LARC. The SPEED model can be used to predict the pCR to nICRT based on the baseline gut microbiome with high robustness and accuracy, thereby assisting clinical physicians in providing individualized management for patients with LARC.

FUNDING: This research was funded by the China National Natural Science Foundation (82202884).

Для цитирования: Yang Zhengyang, Ma Jingxin, Han Jiagang, Li Ang, Liu Gang, Sun Yi, Zheng Jianyong, Zhang Jie, Chen Guangyong, Xu Rui, Sun Liting, Meng Cong, Gao Jiale, Bai Zhigang, Deng Wei, Zhang Chenlin, Su Jianrong, Yao Hongwei, Zhang Zhongtao. Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer.. Med (New York, N.Y.). 2024. DOI: 10.1016/j.medj.2024.07.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.